Journal of Dermatology最新文献

{"title":"Coexisting Faun-Tail Nevus and Aplasia Cutis Without Dysraphism: A Rare Association","authors":"Sonika Garg, Lekshmi P. Kumar, Vishal Gaurav","doi":"10.1111/1346-8138.17865","DOIUrl":"10.1111/1346-8138.17865","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"e698-e699"},"PeriodicalIF":2.7,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of Drugs Associated With the Development of Bullous Pemphigoid: A Nationwide Study","authors":"Min Jae Kim,&nbsp;Bo Ri Kim,&nbsp;Kun Hee Lee,&nbsp;Hyun Jeong Ju,&nbsp;Jung Min Bae,&nbsp;Chong Won Choi,&nbsp;Sang Woong Youn","doi":"10.1111/1346-8138.17809","DOIUrl":"10.1111/1346-8138.17809","url":null,"abstract":"<div>\u0000 \u0000 <p>Bullous pemphigoid (BP) is an autoimmune blistering skin disorder with an increasing incidence, particularly among older adults. Given the role of medications in developing drug-associated BP (DABP), exploring drugs that cause DABP is crucial for prescribing appropriate drugs to prevent BP development. This study aimed to identify drugs associated with DABP. In this nationwide retrospective cohort study, we compared 5066 patients newly diagnosed with BP with 10 132 matched controls. We first established a comprehensive drug list of all medications used in our country and conducted a case–control study to identify candidate drugs associated with DABP. To validate these associations, we performed a separate cohort study, enrolling patients with a confirmed diagnosis of BP and matched controls. In the screening stage, 88 drugs were associated with an increased risk of DABP, while 27 drugs were linked with a reduced risk. Validation confirmed that 78 drugs increased the risk of DABP, whereas 22 drugs lowered it. Among the candidate drugs, anti-diabetic medications, including dipeptidyl peptidase-4 (DPP4) inhibitors and sulfonylureas, neuropsychiatric drugs such as benserazide and carbidopa (used for Parkinson's disease) and donepezil and memantine (for Alzheimer's disease), increased the risk of DABP. Conversely, several anti-inflammatory medications, including meloxicam and celecoxib and lipid-lowering agents, such as rosuvastatin and atorvastatin, have been found to lower the risk of DABP. Lastly, diazepam, diltiazem, and <i>Ginkgo biloba</i> extracts exhibited protective effects against DABP development. This nationwide study, employing an unbiased analysis of all medications in our country, highlights a substantial number of medications linked to the development of DABP. Our study provides practical insights for drug selection to prevent the development of DABP in elderly patients.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1304-1313"},"PeriodicalIF":2.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Atypical Case of Angioedema With Normal C1-Inhibitor Responding to Both C1-Inhibitor Concentrate and Omalizumab","authors":"Koji Miyahara,&nbsp;Marie Matsumoto,&nbsp;Masaki Kunihiro,&nbsp;Yoichiro Toi,&nbsp;Michihiro Hide","doi":"10.1111/1346-8138.17838","DOIUrl":"10.1111/1346-8138.17838","url":null,"abstract":"<div>\u0000 \u0000 <p>Angioedema is classified into mast cell-mediated and bradykinin-mediated types. Mast cell-mediated angioedema (AE-MC) frequently presents with wheals and may respond to antihistamines and/or corticosteroids. In contrast, bradykinin-mediated angioedema (AE-BK) neither accompanies urticaria nor responds to these treatments, but may respond to medications targeting bradykinin or molecules involved in its production pathway. Hereditary angioedema (HAE), a subtype of AE-BK, includes a small population of HAE that exhibit normal C1 inhibitor (C1-INH) levels, classified as HAE with normal C1-INH (HAE-nC1INH). However, genetic abnormalities are not identified in most cases, complicating the differentiation from AE-MC. We present a case of a 41-year-old woman with recurrent gastrointestinal edema with abdominal pain, and marked swelling of the abdomen and extremities without C1-INH deficiency. Neither family history nor genetic mutations were identified; however, her symptoms, including the lack of urticaria, and resistance to antihistamines and corticosteroids were consistent with AE-BK. Considering the possibility of AE-BK including HAE-nC1INH, she received intravenous plasma-derived C1-INH (pdC1-INH) from Day 112 (with Day 0 as her first visit) when an attack occurred, resulting in a substantial reduction of symptom severity. From Day 266, she was treated with q4w 300 mg omalizumab and her attack-related symptoms largely reduced throughout the course without further administrations of pdC1-INH. This case suggests a certain level of overlap between AE-BK and AE-MC, and the importance of trying anti-immunoglobulin E medications for refractory angioedema.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1330-1333"},"PeriodicalIF":2.7,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived Stigma and Mental Health Disorders Among Adults With Alopecia Areata Living in Japan","authors":"Norimitsu Saito,&nbsp;Kazumasa Kamei,&nbsp;Genevieve Gautier,&nbsp;Samantha K. Kurosky,&nbsp;Kent A. Hanson,&nbsp;Griffith Bell,&nbsp;Lulu Lee,&nbsp;Nikoletta Sternbach,&nbsp;Akira Yuasa","doi":"10.1111/1346-8138.17831","DOIUrl":"10.1111/1346-8138.17831","url":null,"abstract":"<p>Alopecia areata (AA) is a common disorder that causes hair loss and can significantly impact quality of life, which may be partially due to AA-related stigma. Examining the impact of AA on psychosocial health is important for understanding the burden experienced by patients with AA. The primary objective of this study was to examine mental health and sleep conditions, hair growth satisfaction, and AA-related stigma perceptions among individuals diagnosed with AA in Japan. The study used patients' self-reported data collected from the National Health and Wellness Survey conducted in Japan in 2023. Collected data included demographic characteristics and comorbidities; among those with a self-reported clinical diagnosis of AA, additional information on clinical characteristics, treatments, and perceived AA-related stigma was captured. Results were analyzed and stratified by self-assessed disease severity. Among the full sample (30 013 adults living in Japan), 471 respondents reported a clinical diagnosis of AA, including 347 mild cases, 100 moderate cases, and 24 severe cases. A diagnosed mental health disorder in the past year was reported by 57 respondents (12.1%), and 67 (14.2%) reported a diagnosed sleep condition in the past year. Less than half of respondents (47.4%) were satisfied with their current hair growth, and satisfaction decreased with increasing disease severity. Overall, 70.3% of respondents reported feelings of embarrassment, 55.0% felt that others judged them negatively, and 50.3% felt that others treated them negatively due to AA. A higher proportion of respondents with a severe case (54.2%) reported feeling embarrassed to have AA “very much so” compared with respondents who had mild (15.3%) or moderate (26.0%) cases. Perceived AA-associated stigma increased with disease severity. Overall, this study demonstrated the prevalence of AA-related disease stigma and mental health conditions among individuals with AA living in Japan, underscoring the importance of mental health support for patients with AA.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1255-1262"},"PeriodicalIF":2.7,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17831","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment for Atopic Dermatitis-Induced Rash on the Face and Neck: Efficacy at Reducing Local Side Effects of Topical Steroid and Tacrolimus Ointment","authors":"Masatoshi Abe,&nbsp;Atsuyuki Igarashi,&nbsp;Hiroyuki Kitajima,&nbsp;Hiroyuki Toyama,&nbsp;Kenji Kabashima,&nbsp;Hidehisa Saeki","doi":"10.1111/1346-8138.17817","DOIUrl":"10.1111/1346-8138.17817","url":null,"abstract":"<p>This open-label, single-arm, multicenter clinical study evaluated the treatment satisfaction, efficacy, and safety of 0.5% delgocitinib ointment twice daily for 12 weeks, applied to face/neck lesions caused by ≥ 3 months use of topical steroids or tacrolimus ointment in patients with atopic dermatitis (AD). The primary endpoint was change in treatment satisfaction (Treatment Satisfaction Questionnaire for Medication-9 [TSQM-9]). Secondary endpoints included changes in modified Eczema Area and Severity Index (mEASI) and EASI scores, the numerical rating scale (NRS) for pruritus, the severity of side effects, skin condition at target lesions, disease control (Atopic Dermatitis Control Tool [ADCT]), and preference for delgocitinib ointment (Patient Preference Questionnaire [PPQ]). Overall, 38 patients (mean age 40 years) with a duration of AD of 30.7 years were included in the study. Scores of TSQM-9 for global satisfaction (Week 0: 58.8 ± 14.7; Week 4: 68.5 ± 16.6; Week 12: 73.2 ± 16.0), effectiveness (57.0 ± 14.1; 67.0 ± 12.6; 70.9 ± 13.4), and convenience (64.9 ± 15.0; 73.6 ± 12.7; 76.1 ± 13.6) (all cases <i>p</i> &lt; 0.01), mEASI (Week 0: 1.31; Week 12: 0.68, <i>p</i> &lt; 0.001) and NRS (4.53; 2.71, <i>p</i> &lt; 0.001) scores, and ADCT (8.3; 5.6, <i>p</i> &lt; 0.01) were improved significantly. Compared with that at Week 0, the incidence of ≥ mild skin atrophy, telangiectasia, and skin irritation decreased. The PPQ showed that approximately 80% of patients rated all queries as “strongly agree” or “agree.” In addition, skin conditions were significantly improved for all items (dryness, feel, firmness/elasticity, and appearance) at 1–2 weeks and 12 weeks (<i>p</i> &lt; 0.001). The present results demonstrate that delgocitinib ointment might be an effective option for switching treatment for face/neck AD in patients with skin lesions, or for those who are concerned about the development of side effects related to steroids or tacrolimus.</p><p><b>Trial Registration:</b> Japan Registry of Clinical Trials (jRCTs031230063)</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1232-1242"},"PeriodicalIF":2.7,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17817","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Molecular Subtyping Revealed Molecular Pathways That Contribute to the Pathogenesis of Rosacea","authors":"Ximin Hu,&nbsp;Libei Liu,&nbsp;Yingxue Huang,&nbsp;Yiya Zhang,&nbsp;He Zhao,&nbsp;Han Zhao,&nbsp;Yi Guo,&nbsp;Hongfu Xie,&nbsp;Zhili Deng,&nbsp;Mengting Chen,&nbsp;Ji Li","doi":"10.1111/1346-8138.17798","DOIUrl":"10.1111/1346-8138.17798","url":null,"abstract":"<div>\u0000 \u0000 <p>The latest progress in rosacea research over the past two decades has revealed important limitations of the current clinical subtyping approach. A new framework of rosacea molecular subtyping is urgently needed to gain insight into the pathogenesis of rosacea. Here, we propose a novel molecular subtype of rosacea based on pathogenetic progression using gene set enrichment analysis (GSEA) and consensus clustering analysis. We identified molecular pathways that contribute to the severity of rosacea. Specifically, the renin angiotensin system (RAS) pathway contributes to erythema and flushing in the mild stage, and the gradual activation of inflammatory pathways and decreased metabolism and biosynthesis were found to be correlated with the severity of rosacea. In addition, angiogenesis and neutrophil activation may contribute to persistent erythema and a large number of papules and pustules in the severe stage of rosacea. Finally, the transcription factor (TF) regulatory network revealed that the key TFs (<i>ETV4</i>, <i>ETS1</i>, <i>USF1</i>, <i>IFR1</i>, <i>NFKB1</i>, and <i>STAT1</i>) and their targets regulated the RAS, inflammatory, and angiogenesis pathways, contributing to the pathogenesis of rosacea. This work correlated molecular subtyping of rosacea with its pathogenetic progression, which provided insight into the pathogenesis and therapeutic strategies for rosacea patients of different severity.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1285-1296"},"PeriodicalIF":2.7,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disrupted B-Cell Cytokine Homeostasis in Psoriasis: The Impact of Elevated IL-6 and Impaired IL-10 Production","authors":"Tasuku Kitano,&nbsp;Motoki Horii,&nbsp;Kenta Kudo,&nbsp;Jiro Nishio,&nbsp;Ko Fujii,&nbsp;Natsumi Fushida,&nbsp;Kie Mizumaki,&nbsp;Yasuhito Hamaguchi,&nbsp;Takashi Matsushita","doi":"10.1111/1346-8138.17804","DOIUrl":"10.1111/1346-8138.17804","url":null,"abstract":"<div>\u0000 \u0000 <p>Psoriasis is a chronic inflammatory skin disease driven by immune dysregulation. This study explores the role of B cells, particularly cytokine-producing subsets, in psoriasis pathogenesis. Although T cells, particularly Th17, have been well documented in psoriasis, recent evidence suggests that B cells contribute to the disease process. Flow cytometry analysis of 50 psoriasis patients and 20 healthy controls revealed a significant increase in IL-6–producing effector B cells (Beffs) and a decrease in IL-10–producing regulatory B cells (Bregs) in psoriasis patients. As IL-6 is pro-inflammatory and IL-10 is anti-inflammatory, this imbalance likely exacerbates inflammation in psoriasis. The study also examined the effects of guselkumab, an IL-23 inhibitor, on cytokine-producing B cells. The frequency of IL-6–producing Beffs in the blood was significantly (<i>p</i> &lt; 0.05) elevated in patients with psoriasis compared with that in healthy controls. In contrast, the frequency of IL-10–producing Bregs in the blood was significantly (<i>p</i> &lt; 0.05) decreased in patients with psoriasis compared with that in healthy controls. In 10 biologic-naïve psoriasis patients, guselkumab significantly reduced IL-6–producing Beffs 4 weeks posttreatment, corresponding with a marked decrease in the Psoriasis Area and Severity Index (PASI). However, IL-10–producing Bregs showed no significant change over this period, suggesting that regulatory B cell recovery may require a longer timeframe or additional stimuli. These findings highlight the potential of B cells as biomarkers for disease activity and therapeutic response in psoriasis. The observed cytokine imbalance suggests that targeting B cell-mediated inflammation could be a novel therapeutic avenue. Further research is needed to assess long-term Breg dynamics and their role in maintaining immune homeostasis in psoriasis. This study reinforces the importance of both effector and regulatory B cells in psoriasis and suggests that monitoring their balance may improve disease characterization and treatment strategies.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1297-1303"},"PeriodicalIF":2.7,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory Post-Zoster Eosinophilic Dermatitis of the Eyelids Successfully Treated With Mycophenolate Mofetil","authors":"Takahiro Hase,&nbsp;Yasuyuki Fujita,&nbsp;Kodai Miyamoto,&nbsp;Satoko Shimizu","doi":"10.1111/1346-8138.17833","DOIUrl":"10.1111/1346-8138.17833","url":null,"abstract":"<div>\u0000 \u0000 <p>Post-zoster eosinophilic dermatitis is a rare skin disease caused by the infiltration of eosinophils into the dermis at the site of healed herpes zoster lesions. Since its initial report by Mitsuhashi and colleagues in 1997, there have been only 11 documented cases, predominantly among Asian patients. Most cases can be treated effectively with topical corticosteroids. We report a case of post-zoster eosinophilic dermatitis with a peculiar clinical manifestation and refractory course. A Japanese woman in her 40s presented with persistent pain and swelling of the right eyelid after treatment for herpes zoster in the right ophthalmic nerve. Histologically, the diffuse inflammatory infiltration of lymphocytes and eosinophils was noted in the entire dermis. Despite various treatments in addition to prednisolone, the symptoms did not improve for approximately 1 year. Eventually, systemic corticosteroid in addition to mycophenolate mofetil induced remission. This is first report of this combination for the treatment of post-zoster eosinophilic dermatitis. This case underscores the need for systemic therapy to treat refractory cases of post-zoster eosinophilic dermatitis, deviating from the more common topical corticosteroid therapy. The differential diagnosis of post-zoster eosinophilic dermatitis includes eosinophilic diseases such as eosinophilic pustular folliculitis, angiolymphoid hyperplasia with eosinophilia, and Kimura's disease, which require careful clinicopathologic investigation. This case adds to a new treatment option to our limited understanding of post-zoster eosinophilic dermatitis and its management.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1326-1329"},"PeriodicalIF":2.7,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Real-World Outcomes of Baricitinib in Severe Alopecia Areata: A 104-Week Retrospective Analysis From a Single Institute","authors":"Moyuka Wada-Irimada,&nbsp;Takehiro Takahashi,&nbsp;Mana Sekine,&nbsp;Toshiki Okazaki,&nbsp;Takuya Takahashi,&nbsp;Tomoko Chiba,&nbsp;Emi Yamazaki,&nbsp;Kosuke Shido,&nbsp;Toshiya Takahashi,&nbsp;Masato Mizuashi,&nbsp;Yoshihide Asano","doi":"10.1111/1346-8138.17829","DOIUrl":"10.1111/1346-8138.17829","url":null,"abstract":"<div>\u0000 \u0000 <p>Baricitinib, a Janus kinase inhibitor, demonstrated efficacy in achieving scalp hair regrowth in severe alopecia areata (AA). While short-term real-world data on its efficacy have been reported, long-term data remain limited. This retrospective observational study spanning 104 weeks analyzed clinical trajectories of 51 severe AA patients treated with baricitinib. Among them, 36 continued treatment for 104 weeks, with 55.6% achieving a SALT score of ≤ 20 and 72.2% achieving ≥ 30% improvement from baseline in SALT score (SALT₃₀). Multivariate analysis identified female sex and disease duration &lt; 4 years as significant predictors of response. Furthermore, patients with eyebrow or eyelash regrowth at 52 weeks had a higher likelihood of achieving long-term scalp hair regrowth. We identified a subgroup of markedly slow responders who achieved SALT₃₀ between 52 and 104 weeks, many of whom had eyebrow or eyelash regrowth at 52 weeks. Baricitinib was well tolerated throughout the study period, with no serious long-term adverse effects. Our findings supported baricitinib's long-term efficacy and safety and suggested predictive factors for treatment responses in severe AA.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1321-1325"},"PeriodicalIF":2.7,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do female patients see their physicians differently? A population-based study evaluating perception of physician communication by patients with hidradenitis suppurativa","authors":"Lucy F. Harvey,&nbsp;Paige Kingston,&nbsp;Robin Kikuchi,&nbsp;Artur Manasyan,&nbsp;Kaviyon Sadrolashrafi,&nbsp;Audrey Hao,&nbsp;Hannah Tolson,&nbsp;Danielle Yee,&nbsp;April W. Armstrong","doi":"10.1111/1346-8138.17699","DOIUrl":"10.1111/1346-8138.17699","url":null,"abstract":"<p>Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition that causes painful abscesses, nodules, fistulae, and fibrotic scars. Management of HS requires strong physician–patient communication; however, it is not known if male and female HS patients perceive physician communication differently. This study aimed to determine if patient-perceived quality of physician communication differs between male and female HS patients. This was a population-based, cross-sectional study using the Medical Expenditure Panel Survey from 2002 to 2015 and 2018. Linear univariate and multivariate regression analyses were used to compare male and female patients' perceptions regarding how well physicians (1) demonstrated respect (2) listened to patients, (3) explained information, and (4) spent sufficient time with patients. A total of 91,619 (weighted) HS patients aged 21–85 were included: 25,175 males (27.18%) and 66442 females (72.52%). On multivariate linear regression, compared to male patients, female patients perceived that clinicians were significantly worse at demonstrating respect (<i>ꞵ</i> = −0.231, 95% confidence interval [CI] = −0.351 to −0.111, <i>p</i> = 0.003), listening (<i>ꞵ</i> = −0.286, 95% CI = −0.391 to −0.181, <i>p</i> = 0.001), and explaining concepts (<i>ꞵ</i> = −0.133, 95% CI = −0.267 to −0.000, <i>p</i> = 0.050). Findings were adjusted for age, race, ethnicity, income, insurance, education, and medical comorbidities. Female and male patients did not differ significantly in perceptions of time spent with clinicians (<i>ꞵ</i> = −0.149, 95% CI = −0.362 to 0.064, <i>p</i> = 0.138). On subgroup analysis, both male and female patients perceived female physicians to better spend time with them compared male physicians (3.71 vs 3.32, <i>p</i> = 0.023). In conclusion, male patients with HS perceived better physician communication in regard to physician respect, listening, and explanations. Thoughtful physician communication is crucial in managing HS and may be especially important when treating female patients.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1263-1273"},"PeriodicalIF":2.7,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}